Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01014793

Enrollment

Registered

2009-11-17

Start date

2005-05-31

Completion date

2008-12-31

Last updated

2009-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Keywords

Acromegaly resistant, combined-treatment, dopamine agonist

Brief summary

In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.

Interventions

DRUGcabergoline

cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Active disease, under octreotide treatment at least 9 months

Exclusion criteria

* Cabergoline allergy

Design outcomes

Primary

Measure	Time frame
Control of IGF-I levels	six months

Secondary

Measure	Time frame
control IGI-I levels	six months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026